Summary & Overview
HCPCS Level II Q5153: Injection, aflibercept-yszy (Opuviz), 1 mg
HCPCS Level II code Q5153 denotes the injection of aflibercept-yszy (Opuviz), a 1 mg biosimilar formulation of the intravitreal anti-VEGF agent aflibercept. Nationally, biosimilar ophthalmic injections influence drug spend, provider billing workflows, and patient access to lower-cost biologic alternatives for retinal conditions that require intravitreal therapy.
This analysis covers reimbursement and coverage patterns across major national payers: Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare and Medicare. Readers will find a concise overview of coding context and clinical use, payer coverage considerations, typical sites of service, and common billing modifiers used with intravitreal biologic injections. The publication summarizes benchmark metrics, policy updates affecting biosimilar adoption in ophthalmology, and practical coding notes relevant to billing teams and revenue cycle staff.
The content is focused on national implications for clinicians, coders, and administrators seeking clarity on how HCPCS Level II code Q5153 is used in practice, how payers approach coverage of biosimilar intravitreal agents, and what operational areas (claims submission, site-of-service designation, and documentation) typically require attention.
Billing Code Overview
HCPCS Level II code Q5153 describes an injection of aflibercept-yszy (Opuviz), biosimilar, 1 mg. This code represents a single-dose administration of a biosimilar intravitreal anti-VEGF agent used in ophthalmic care for conditions that require intraocular injection of aflibercept.
-
Service type: Intravitreal medication administration
-
Typical site of service: Ophthalmology clinic, outpatient ambulatory surgery center, or other outpatient ophthalmic procedure setting
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with neovascular (wet) age-related macular degeneration or diabetic macular edema presenting to an ophthalmology clinic for an intravitreal anti-VEGF injection. The patient has baseline visual acuity and intraocular pressure documented, informed consent obtained, and topical or intracameral anesthesia applied. The clinical workflow includes pre-procedure assessment (recent ocular history, allergy review, and medication reconciliation), application of antiseptic (povidone-iodine), placement of a lid speculum, measurement of the injection site, and administration of Q5153 (injection, aflibercept-yszy, biosimilar, 1 mg) into the vitreous cavity. Post-injection instructions are provided and the patient is observed briefly for acute complications (pain, vision loss, redness, or signs of endophthalmitis). Follow-up visits for visual acuity, optical coherence tomography, and possible repeat injections are scheduled according to disease activity.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when the intravitreal injection required substantially greater effort, time, or complexity than typical (document rationale and time). |
52 |